A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression.

@article{Caligiuri2005APC,
  title={A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression.},
  author={M. Caligiuri and F. Becker and K. Murthi and F. Kaplan and S. Dédier and C. Kaufmann and A. Machl and G. Zybarth and J. Richard and N. Bockovich and A. Kluge and N. Kley},
  journal={Chemistry \& biology},
  year={2005},
  volume={12 10},
  pages={
          1103-15
        }
}
The identification of molecular determinants of tumor cell survival is an important objective in cancer research. Here, we describe a small-molecule kinase inhibitor (RGB-286147), which, besides inhibiting tumor cell cycle progression, exhibits potent cytotoxic activity toward noncycling tumor cells, but not nontransformed quiescent fibroblasts. Extensive yeast three-hybrid (Y3H)-based proteome/kinome scanning with chemical dimerizers revealed CDK1/2/3/5/7/9 and the less well-characterized CDK… Expand
Cyclin-dependent kinase inhibitors as anticancer drugs.
TLDR
Progress in the preclinical development of CDK inhibitors and their anticancer activities is reported, and the links between their ability to inhibit transcription and sensitisation of some types of cancer to apoptosis, mechanisms leading to p53 activation, and their synergistic cooperation with common DNA damaging drugs are discussed. Expand
The Cyclin-Dependent Kinase (CDK) Family Member PNQALRE/CCRK Supports Cell Proliferation but has no Intrinsic CDK-Activating Kinase (CAK) Activity
TLDR
The data do not support the proposed function of PNQALRE/CCRK in activating CDKs, but reinforce the notion of Cdk7 as the major, and to date the only, CAK in mammalian cells. Expand
Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology.
TLDR
There are strong signs that CDK9 inhibition would be a useful therapeutic strategy in all three indications, but the lack of selective inhibitors has so far confounded clinical development. Expand
CDK inhibitors in cancer therapy, an overview of recent development.
  • Mengna Zhang, Lingxian Zhang, +5 authors C. Cai
  • Medicine
  • American journal of cancer research
  • 2021
TLDR
The efficacy and discrepancy of combination therapy with CDK inhibitors and PD1/PDL1 antibodies were analyzed, which might give insights into the development of promising strategy for cancer treatment. Expand
Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked
TLDR
CDK inhibitors dramatically reduced levels of the anti-apoptotic proteins, Mcl-1 and XIAP, but siRNA-mediated suppression of Mcl/cyclin complexes did not induce cell death in the osteosarcoma cells used in this study. Expand
CCRK is a novel signalling hub exploitable in cancer immunotherapy
TLDR
The multifaceted tumor‐intrinsic and extrinsic functions of CCRK are summarized, which represents a novel signalling hub exploitable in cancer immunotherapy. Expand
The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells.
TLDR
Results indicate a modulation of DNA double-strand break repair to be partially attributed to the radiosensitization effects of SNS-032 observed in hypoxic and quiescent lung tumor cells, indicating the importance of therapy resistance for the radiocurability of solid tumors. Expand
Effects of Cyclin Dependent Kinase 9 inhibition on zebrafish larvae
TLDR
It is demonstrated that CDK9 clearly plays a fundamental role in early cellular growth and proliferation in zebrafish larvae, and for the first time,CDK9 is localized at a subcellular level in whole-mounted larvae. Expand
Identification of Yin-Yang Regulators and a Phosphorylation Consensus for Male Germ Cell-Associated Kinase (MAK)-Related Kinase
TLDR
It is established that human CDK-related kinase CCRK is an activating T157 kinase for MRK, whereas active CDK7/cyclin H/MAT1 complexes phosphorylate CDK2 but not MRK. Expand
CDK9/cyclin T1: a host cell target for antiretroviral therapy
TLDR
This review outlines the advantages and prospects of selective CDK9 inhibitors in HIV replication and suggests that other than direct antiviral agents, that inhibit HIV replication through a direct interaction with viral proteins, CDK 9 inhibitors might not suffer from the emergence of resistant virus strains. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 48 REFERENCES
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
TLDR
Results indicate that inhibition of Cdk4/6 alone is sufficient to cause tumor regression and a net reduction in tumor burden in some tumors. Expand
Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians.
TLDR
CDKIs have shown promise as neuroprotective agents in the research laboratory and, in the future, may prove useful in the neurology clinic. Expand
Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.
TLDR
A simple batchwise affinity chromatography approach using two purine derivatives facilitated isolation of a small set of highly purified kinases suggests that this could be a general method for identifying intracellular targets relevant to a particular class of ligands. Expand
Pharmacological inhibitors of cyclin-dependent kinases.
TLDR
Pharmacological inhibitors of CDKs are currently being evaluated for therapeutic use against cancer, alopecia, neurodegenerative disorders, cardiovascular disorders, viral infections and parasitic protozoa. Expand
Inhibition of Human Immunodeficiency Virus Type 1 Transcription by Chemical Cyclin-Dependent Kinase Inhibitors
TLDR
It is suggested that cdk's are required for efficient HIV-1 transcription and, therefore, specific cdk inhibitors are proposed as potential antiviral agents in the treatment of AIDS. Expand
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists.
TLDR
It is reported that cell membrane-permeable forms of such peptides preferentially induced transformed cells to undergo apoptosis relative to nontransformed cells, suggesting that deregulation of E2F and inhibition ofcdk2 are synthetically lethal and provide a rationale for the development of cdk2 antagonists as antineoplastic agents. Expand
An efficient proteomics method to identify the cellular targets of protein kinase inhibitors
  • K. Godl, J. Wissing, +8 authors H. Daub
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2003
TLDR
Efficient affinity purification techniques can be developed for other protein kinase inhibitors, providing crucial information about their cellular modes of action and might have significant implications on the development of p38 inhibitors as antiinflammatory drugs. Expand
Chemical Proteomic Analysis Reveals Alternative Modes of Action for Pyrido[2,3-d]pyrimidine Kinase Inhibitors*
TLDR
The utility of proteomic methods employing immobilized kinase inhibitors for identifying new targets linked to previously unrecognized therapeutic applications is demonstrated, and pyrido[2,3-d]pyrimidines did not discriminate between tyrosine and serine/threonine kinases. Expand
Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF.
TLDR
It is shown that, despite its ubiquitous expression, CDK2 exhibits tissue-specific regulation by the essential melanocyte lineage transcription factor MITF, and it may be a suitable drug target in melanoma. Expand
Cyclins That Don’t Cycle : Cyclin T/Cyclin-Dependent Kinase-9 Determines Cardiac Muscle Cell Size
TLDR
In transgenic mice, activation of Cdk9 activity via cardiac-specific overexpression of cyclin T1 suffices to provoke hypertrophy, and these results support the logic of examining Cdk 9 as a potential drug target in heart disease. Expand
...
1
2
3
4
5
...